Mechanism

HER2; HER3 (blocks NRG1 binding to HER3)

Assets acting on this target.

Class
HER2 x HER3 bispecific antibody (zenocutuzumab / Bizengri)
Pathway
Blocks NRG1-driven HER2:HER3 dimerization, downstream PI3K/AKT/mTOR and RAS/MAPK signaling
Research

Explore this mechanism at different depths

Research adds deeper and simplified explanation variants while preserving the same scientific register and source caveats.

Company

1 of 1 assets

Zenocutuzumab
Monoclonal antibodyApproved

← all assets